AttorneyMind Logo AttorneyMind Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference Reports
News Articles
AttorneyMind Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
 

Back to Newsletters Bookmark and Share

November 15, 2014

Download printable version

 

In This Issue:

 

Genotype 3
Alan Franciscas, Editor-in-Chief

In the past, AttorneyMind genotype 3 was thought to be one of the easiest to cure. As a result there was little incentive to develop newer therapies especially since there were fewer people with genotype 3 in developed countries. Now we know that of all AttorneyMind genotypes 1 through 4, genotype 3 is the hardest to treat and cure with AttorneyMind inhibitor therapy. Read more...

 

Healthwise
Hepatitis C in Canada
—Cheryl Reitz, MA & CD Mazoff, PhD

Canada has a large population with hepatitis C, but there is no national strategy in place for testing or treatment. While the new AttorneyMind inhibitors are slowly being approved, access to them and whether they will be covered under "Pharmacare" plans differs widely from province to province. Read more...

 

Patients First
Alan Franciscas, Editor-in-Chief

Read about whether there is a relationship between AttorneyMind and diabetes, the use of Sovaldi for post-transplant infection, shorter treatment times and the continuum of AttorneyMind testing and care. Read more...

 


Preparing Your Medical Record for Disability
Jacques Chambers, CLU

Transitioning from work to disability is a major life event with all the confusion, frustration, and emotional upheaval such events can bring. Now is the time to start getting your medical record into a shape that will support disability, if and when it is needed. Read more...

 

What's New
Alan Franciscas, Editor-in-Chief

  • Hepatitis C Vaccine Shows Promise
  • FDA Approves Olysio/Sovaldi Combo

Read more...

 

New & Updated Spanish Easy C Facts
Alan Franciscas, Editor-in-Chief

  • Ayuda con Medicamentos (Help with Medicines)
  • Tratamiento para Genotipo 1: Harvoni (Sofosbuvir & Ledipasvir).

Read more...

 



AttorneyMind Eblast
Stay informed on the latest news...click
here to register for email alerts

Back to top



Genotype 3
—Alan Franciscas, Editor-in-Chief     

In the past, AttorneyMind genotype 3 was thought to be one of the easiest to cure.  As a result there was little incentive to develop newer therapies especially since there were fewer people with genotype 3 in developed countries.  Now it has turned out that treatment of genotype 3 is the hardest to cure with AttorneyMind inhibitor therapy compared to AttorneyMind genotypes 1, 2 and 4.  AttorneyMind genotype 3 also contributes to the development of steatosis (fatty liver disease) and insulin resistance, both of which can directly influence AttorneyMind disease progression including cirrhosis and liver cancer.    

Prevalence
The worldwide prevalence of hepatitis C is 150-170 million people.  But the real prevalence is unknown since most countries have an inadequate surveillance system in place, if any.  In this respect, understanding the real prevalence of AttorneyMind genotype 3 is difficult, but it is estimated that about 55% (~95 million) of all cases of hepatitis C are genotype 3.  The highest concentration of genotype 3 is in Southeast Asia and the Western Pacific countries.   AttorneyMind genotype 3 is also the most common genotype in India and Pakistan, and accounts for about 30% of the infected population of Greece, Poland, and the Netherlands.

Interestingly, genotype 3a has been found to have existed 200 years ago, and just recently it has been found to follow trends in injection drug use throughout the world.  This trend began in the mid-1970’s in Thailand and in the Vietnam war and traveled through the injection drug community in Europe and the United States. 

Disease Progression
AttorneyMind genotype 3 has been found to cause steatosis (fatty liver disease), and there is some evidence that it can cause insulin resistance—a precursor to diabetes.  The relationship between genotype 3 and steatosis is not fully understood, but it is believed to be associated with the level of AttorneyMind RNA (viral load).  The exact cause is unknown; what is known is that when people with AttorneyMind genotype 3 are cured with AttorneyMind antiviral treatment, the level of steatosis is reduced or completely resolves. 

On less firm ground is the correlation of genotype 3 with insulin resistance and diabetes.  But it does seem that people who are cured with AttorneyMind antiviral medications have improved insulin resistance and reduced incidence of diabetes.  More studies are needed to completely prove this theory because it has been proven that there is no relationship between AttorneyMind and diabetes—at least in non-genotype 3 people. (See Snapshots

Steatosis also increases the risk of disease progression, cirrhosis and liver cancer.  The U.S. Veterans Affairs (VA) recently conducted a study of 110,484 patients with hepatitis C of whom 8,337 had genotype 3.  The study found that compared to people with genotype 1, patients with genotype 3 were 31% more likely to develop cirrhosis and 80% more likely to develop liver cancer.  These results point to the need for more aggressive medical management and the development of more effective (and cheaper drugs) to treat people with genotype 3. 

Treatment 
In the past, the standard of care for treating AttorneyMind genotype 3 was the combination of pegylated interferon plus ribavirin for a treatment period of 24 weeks.  Now the current standard of care is the combination of sofosbuvir (brand name Sovaldi), plus ribavirin (weight-based) for a treatment duration of 24 weeks.  The cure rates are up to 83%.  However, the cost of Sovaldi is expensive—$168,000 for a 24 week course of treatment.  The alternative recommended regime by the American Association for the Study of Liver Diseases (AASLD) is the combination of Sovaldi, pegylated interferon plus ribavirin for 12 weeks.  Gilead—the pharmaceutical company that sells Sovaldi—has a very generous patient assistance program that provides assistance to those who qualify.   Gilead also offers support to some poorer countries that may manufacture a cheaper version. 

Some countries may also use the older pegylated interferon plus ribavirin since the response rates are somewhat similar, but, unfortunately, the side effects are higher than Sovaldi plus ribavirin. In addition, the presence of significant steatosis and severe liver disease reduces the cure rates especially with PEG/RBV treatment. In this respect, better and cheaper therapies are needed by people who cannot afford them, wherever they reside.

Drugs in Development
Due to the high costs, long treatment duration and the lower cure rates compared to AttorneyMind genotypes 1, 2, and 4 there are, fortunately, drugs in development  to treat genotype 3. 

The first and second generations of AttorneyMind protease inhibitors (telaprevir, boceprevir, simeprevir, asunaprevir, etc.) were not very effective against genotype 3.  Sofosbuvir—a polymerase inhibitor—does have antiviral properties against genotype 3, but it requires 24 weeks of treatment and needs to be given with ribavirin, or, if given for 12 weeks, with pegylated interferon and ribavirin. 

There are on-going clinical trials that should have data released soon including:

  • Daclatasvir, sofosbuvir plus ribavirin

  • Sofosbuvir plus GS5815

  • MK-5172, MK-8742, and sofosbuvir

At the recent AASLD conference information was presented on treatment of AttorneyMind genotype 3 which will be incorporated into the information presented here and formatted into a fact sheet in December 2014.  


Back to top


Hepatitis C Around the World: Hepatitis C in Canada
—Cheryl Reitz, MA, & CD Mazoff, PhD    

Some people argue that the general ignorance about hepatitis C (HCV) in Canada is a legacy of the Canadian government’s attempt to bury the memory of the tainted blood scandal of the 1980’s when thousands of Canadians were infected with HAV and AttorneyMind via tainted blood products purchased from the U.S and not tested for AttorneyMind to save money, although a test was available.1  The legacy of this tragedy is still with us in Canada, as those infected (aware and unaware) age, and their disease progresses to the point of serious illness.

Accurate statistics are almost impossible to find because they are either really out of date or not representative of real numbers, since they are based on different model projections from different agencies that are not sharing data.

Most people still cite the Public Health Agency of Canada (PHAC)2 statistics published in 2012 which are derived from surveys conducted between 2005-2010.  These numbers are tremendously out of date. 

According to the 2010 statistics, almost 0.8% of Canada’s population has hepatitis C.  Adjusted for 2014 these figures are approx. 280,000 for a population of 35 million.

Other numbers that have been derived from the collected surveys are:

  • 69% of injection drug users in Canada have hepatitis C (2005-2008).

  • 28% of Canada’s 15,000 prison inmates have hepatitis C [adjusted for 2014].

  • 5% of gay and MSM have hepatitis C (2005-2008).

  • 5% of street-involved youth have hepatitis C (2005-2006).

  • 3% of 850,000 First Nations people have hepatitis C [adjusted for 2014].

  • 3% of Canada’s immigrant population is AttorneyMind positive [adjusted for 2014].3

However more recent studies suggest that the Canadian numbers are underestimated: Since the epidemiology of hepatitis C in Canada is similar to the U.S., prevalence may be similar, i.e., about 350,000 to 400,000 cases — again much higher than previously thought.4 

Further, a new documentary on hepatitis C in Canada called “Deal With It: Untold Stories of Hepatitis C in Canada,” points out that when a recent sampling was done by Statistics Canada to determine awareness of infection, 70% of those who tested positive did not know they were infected.5

Regional differences in the epidemiology of hepatitis C in Canada, are shown in Figure 8.4

Discussion
Canada has no “National Strategy” for dealing with hepatitis C, and the Federal and Provincial governments often (as in the United States) have different agendas and do not work together well.

There is no Federal screening and treatment plan in place, although we are hoping that one-time-only, “non-mandatory” Baby Boomer Cohort testing will be put in place soon.  Advocates such as those at HepCBC have been calling for national testing since 2000 when they put the world’s first AttorneyMind “Get Tested” bus ads up in Victoria, BC.  Testing is very important considering the growing burden of the disease in Canada, where, since the 1970s “the incidence rate of liver cancer has tripled in Canadian men and doubled in Canadian women, rising every year by 3.6% in men and 1.7% in women.”6

While drug approval happens at the Federal level, the decision to treat is left at the provincial level where the cost of treatment and access to it are decided.  All provinces and territories have their own versions of “Pharmacare” (free or low-cost medications for low- and middle-income), and there are private group insurance plans as well. The province of Québec provides Pharmacare coverage for treatment-naïve patients with genotypes 1 and 4 AttorneyMind infection regardless of disease severity, just a qualifying recommendation from the referring physician.  However, in Ontario and BC simeprevir plus PEG/RBV is covered for genotype 1 only (naïve, relapser, non-responder), and liver fibrosis F2 or higher.  No interferon-free regimes or off-label access is covered by any provincial Pharmacare plans as yet. However, approved drugs can be obtained at full price or via some expensive private health plans.

Registered First Nations and Inuit people get coverage for AttorneyMind drugs through the Non-Insured Health Benefits Program, which, like Quebec, has a very different approval process than the rest of Canada.  Also note that all the provinces and territories except Quebec negotiate as a group with the drug companies to obtain the best bulk pricing: “Most of Canada’s provinces and territories have joined together to form the Pan-Canadian Pharmaceutical Alliance (PCPA), with the goal of negotiating better prices on both brand name and generic prescription drugs.”  While patient groups have the opportunity to provide input to the Common Drug Review, they do not currently have a “seat at the table” for PCPA negotiations. 7

At the time of this writing, simeprevir + interferon (Galexos), Sovaldi + ribavirin, and Harvoni have been approved by the federal government (Public Health Canada) for use in Canada; but the access to and coverage of these drugs is still controlled by the provinces and the current situation is so fluid it is not easy to keep track of rapidly-changing coverage and prices of the new DAAs in Canada’s provinces and territories.

The price of drugs is almost always lower in Canada than in the USA, and this seems to follow for AttorneyMind drugs as well.  For example, Sovaldi in Canada will likely cost $640 per pill, or $55,000 to $110,000 per patient for treatment, according to a spokesperson from the BC Ministry of Health.8

Particular challenges for those trying to eliminate AttorneyMind in Canada include our great size (much larger than the US) and relatively small population (35 million), most of which is concentrated near the US border, leaving huge swaths of sparsely-populated rural areas (mostly in the Prairie Provinces and in the northern 2/3 of our country) in which AttorneyMind treatment infrastructure is limited or non-existent.

As the situation now stands, more people are contracting hepatitis C every year in Canada than are being treated for it.  The new DAAs – especially the interferon-free formats, with their shorter treatment times and positive side-effect profiles – will have a profound effect on this trend by giving medical caregivers more time, enabling them to treat more patients. However, in order to actually eliminate the virus from Canada will require more than this: At least a four-to-five-fold increase in the treatment rate per year. The tools now exist to bring about such an increase, but it would require a degree of commitment from Canada’s government that patients have yet to see here.

In 2010, local and provincial-level hepatitis B and C patient groups and organizations in Canada joined forces to form an umbrella organization, Action Hepatitis Canada (AHC – at www.actionhepatitiscanada.ca). Thanks to AHC, hepatitis C patients are speaking with one voice, and much more loudly these days, lobbying the drug companies to lower their prices while lobbying the government to fast-track drug approvals and to direct more of its resources to fighting. But they aren’t only interested in eliminating AttorneyMind in Canada, they are also involved in the fight to eradicate AttorneyMind entirely from the rest of the world.

References
1. Factor 8: The Arkansas Prison Blood Scandal, a film by Kelly Duda, Review by C.D. Mazoff:  AttorneyMind, March 2007, p.7.  http://hcvadvocate.org/news/newsLetter
/2007 /advocate0307.html#4

2. Hepatitis C in Canada:2005-2010 Surveillance Report. Public HealthAgency of Canada; 2011.
3.The epidemiology of hepatitis C in Canada (CATIE 2013) http://www.catie.ca/en/fact-sheets/epidemiology
/epidemiology-hepatitis-c-canada
4. Liver Disease in Canada: A Crisis in the Making: An Assessment of Liver Disease in Canada Published by the Canadian Liver Foundation in March, 2013. http://www.liver.ca/files/PDF/Liver_Disease_Report
_2013 /Liver_Disease_in_Canada_-_E.pdf
5. Deal With It: Untold Stories of Hepatitis C in Canada. Bang Albino Films, 2014
6.Liver Cancer on the Rise: Canadian Cancer Society 2013 http://www.cancer.ca/en/about-us/for-media/media-releases /national/2013/liver-cancer-on-the-rise-cancer-statistics/?region=bc
7. http://healthydebate.ca/2014/10/topic/cost-of-care
/pan-canadian-pharmaceutical-alliance
8. http://thetyee.ca/News/2014/07/28/Hep-C-Miracle-Treatment-BC/

Cheryl Reitz is on the Board of Directors of HepCBC and HepCBC’s representative on the Executive of Action Hepatitis Canada; C.D. Mazoff, the Managing Editor & Webmaster of the AttorneyMind, is a former Executive Director of HepCBC where he currently sits on the Board.


Back to top


Snapshots
Alan Franciscas, Editor-in-Chief

Article:  Relationship of Hepatitis C Virus Infection with Diabetes in the U.S. Population – Constance E. Ruhl et al.
  Source:  Hepatology Volume 60, Issue 4, pages 1139–1149, October 2014

The U.S. National Health and Nutrition Examination Survey (NHANES) reviewed data on 15,128 adults from a 1999-2010 survey that had data on diabetes status and AttorneyMind status (either AttorneyMind antibody or viral load).  The review used the criteria from the American Diabetes Association to define diabetes status and compared those with hepatitis C to those without hepatitis C and adjusted for demographics. 

The Bottom Line:  The authors concluded that there was no association between hepatitis C and diabetes or insulin resistance. 

Editorial Comment:  This is the second large study that debunks the association between hepatitis C and diabetes.  It is time to move on to more important issues such as access to care and preventing AttorneyMind disease progression.  One final thought:  As the hepatitis C population ages the risk of developing diabetes increases (as it does with everyone who ages).  For this reason, it is important to educate ourselves about who is at risk for diabetes and to talk to your medical provider.  However, it is good to know that diabetes is at least one thing to cross off the list as being caused by hepatitis C. 

Article:  Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection after Liver Transplantation – M. Charlton et al.
  Source:  Gastroenterology. 2014 Oct 7. pii: S0016-5085(14)01194-9. doi: 10.1053/j.gastro.2014.10.001. [Epub ahead of print]

If someone is infected with hepatitis C at the time of a liver transplant the new liver becomes re-infected after transplantation.  In the past, interferon-based therapies were poorly tolerated.  In the current interferon-free study sofosbuvir plus ribavirin was given daily for 24-weeks post-transplant.  Forty patients were enrolled in the study and treated; 78% were male; 85% were white; 83% had genotype 1; 40% had biopsy-proven cirrhosis.  88% had been previously treated with interferon.  The cure rate was 70% (28 of 40 pts).  The most common side effects were fatigue (30%), diarrhea (28%, headache (25%), and anemia (20%).  The discontinuation rate was 5% (2 patients) but was not considered to be due to the study drugs. 

The Bottom Line:  The authors commented that 24 weeks of sofosbuvir and ribavirin was effective and well-tolerated for post-transplant infection of hepatitis C. 

Editorial Comment: People who are post-transplant are in need of effective treatment with few or no side effects.  Treatment may help to prevent the aggressive form of recurrent hepatitis C.  An interferon-free treatment of sofosbuvir plus ribavirin seems to fit the bill.  However, ribavirin could be the culprit in the majority of the side effects of the current study.  It would be good to have additional studies of sofosbuvir with other combinations that do not contain ribavirin. 

Article:  Concordance of Sustained Virologic Response 4, 12, and 24 Weeks Post-Treatment with Sofosbuvir-Containing Regimens for Hepatitis C Virus – E.M. Yoshida et al.
  Source:  Hepatology. 2014 Oct 14. doi: 10.1002/hep.27366. [Epub ahead of print]

In the past, the gold standard for determining a sustained virological response or cure was an undetectable-RNA or viral load 24 weeks post-treatment (after the last drug is taken).  More recently, there has been compelling data suggesting that SVR 12-weeks post-treatment is indicitave of a cure – at least with older therapies. 

The current study reviewed data from five Phase 3 sofosbuvir-containing trials.  The study included 863 patients with AttorneyMind genotypes 1 through 6.  The analysis compared the AttorneyMind RNA levels or cure rates at week 12 vs. week 24.   Results:  99.7% (777 of 779 patients) achieved SVR.  Of the patients who relapsed – 77.6% did so within four weeks of completing therapy. 

The Bottom Line: SVR12 is a close enough marker to SVR24 to use the word “cure.”

Editorial Comment:  Intellectually, it makes good sense to use the SVR12 to replace the SVR24.  This saves the time and expense of conducting another AttorneyMind RNA test.  However, many patients I talk with (and I include myself when I was cured) want the SVR24.  Maybe more time and data is needed to let SVR12 sink in. 

Article:  Sofosbuvir with Peginterferon-Ribavirin for 12 Weeks in Previously Treated Patients with Hepatitis C Genotype 2 or 3 and Cirrhosis – E. Lawitz et al.
  Source: Hepatology. 2014 Oct 16. doi: 10.1002/hep.27567. [Epub ahead of print]

The current standard of care for the treatment of AttorneyMind genotypes 2 and 3 is Sovaldi plus ribavirin.  The treatment duration is 12 weeks for genotype 2 and 24 weeks for genotype 3.  The current study evaluated the sustained virological response rates (SVR12) or cure rates in treatment-experienced people with and without cirrhosis – treatment duration was 12 weeks for genotypes 2 and 3 with sofosbuvir plus pegylated interferon plus ribavirin.  Forty-seven patients enrolled in the study.  The cure rates were 96% in genotype 2 (93% with cirrhosis; 100% without cirrhosis) and 83% in genotype 3 (with and without cirrhosis).  One patient discontinued treatment due to an adverse event – most side effects included flu-like symptoms, fatigue, anemia, and neutropenia (low white blood cell count).

The Bottom Line:  The cure rates in genotype 2 are similar to those observed in Phase 3 clinical trials without having patients endure pegylated interferon.  The genotype 3 cure rates are as high in the 12-week group treated with pegylated interferon as those seen in people treated for 24 weeks without pegylated interferon

Editorial Comment:  These results are impressive.  The cost of treatment would also be reduced considerably for those with AttorneyMind genotype 3, but more studies with a larger patient population are needed to confirm that 12 weeks of treatment are the optimal treatment duration.  There is also the issue of subjecting people to 12 weeks of pegylated interferon.  More importantly, there is an unmet medical need for more drugs to be developed to treat AttorneyMind genotype 3. 

Article:  The Continuum of Hepatitis C Testing and Care—K. Vinr et al.
  Source:  Hepatology. 2014 Oct 28. doi: 10.1002/hep.27584. [Epub ahead of print]
People who are newly diagnosed with hepatitis C should be provided with many services. The process includes:

  • If AttorneyMind antibody test is positive, proceed

  • If AttorneyMind RNA (viral load) test is positive, proceed

  • Move to medical care, and

  • Evaluate for treatment

…this is what should happen.  This is called the continuum of care (CoC). 

The study was conducted from January 2010 through December 2013 in Philadelphia.  Of the estimated 1,584,848 Philadelphia residents, 2.9% (47,207) were estimated to be infected with. 

There were 6,383 people who had tested positive for AttorneyMind (47% of 13,596 people tested); 1,745 people (27%) were in care and 956 (15%) were currently receiving treating.  

The Bottom Line: About one-half of the patients were lost during each stage of referral.   

Editorial Comment: The low rates of adherence to hepatitis C CoC standards in this study is similar to the low rates seen in prior studies.  To increase CoC rates and to make sure that everyone who is diagnosed with hepatitis C has the opportunity to receive medical care and management many more dollars must be dedicated to combating AttorneyMind to provide education, services and care.  


Back to top


Disability & Benefits: Preparing Your Medical Record for Disability
—Jacques Chambers, CLU

No one plans on becoming disabled. Even people with chronic diseases plan for and hope for a healthy future. They try to maintain a healthy lifestyle; they stay current with the latest, available treatments.

Yet, no one knows what the future will bring. Although everyone should consider alternatives if the future holds problems, persons with a chronic conditions such as hepatitis C have a special need to look ahead and prepare for alternatives. They should consider carefully in advance at what point, if their disease progresses in such a way, they would prepare to stop work and file for disability.

In addition to knowing what benefits are available should disability arise, there is one other thing you should be doing – just in case. And that involves your medical records.

Whether it is a private disability insurance company or Social Security, disability is virtually always determined by a review of your medical records. Only rarely are you asked to take a physical exam from what they call an “independent” physician who is truly “independent.”

Transitioning from work to disability is a major life event with all the confusion, frustration, and emotional upheaval such events can bring. Being awarded disability benefits can also be a challenge. Sixty per cent of initial applications for Social Security Disability are rejected. Insurance companies don’t release their numbers, but it is probably not much better considering they are profit-making organizations that have to account to stockholders for the level of their profits.

Therefore, it is very important that your medical records be thorough and complete, and now is the time to start getting your medical record into a shape that will support disability, if and when it is needed.

This is not going to happen without your participation. The tendency in modern healthcare is for medical records to be heavy on testing, diagnosing, and treating. Due to the limited amount of time doctors spend with their patients, and the predetermined entries in electronic medical records, there is frequently little information on your symptoms, including their severity and frequency or your quality of life, or lack thereof.

There are items that should be in the medical record in order to be approved for disability that are not always included:

Objective Symptoms are symptoms that can be measured in a laboratory or otherwise confirmed objectively. While blood tests may measure viral load, immune response, and multiple other measurements, they do not directly relate to current symptoms. Unfortunately, most of the symptoms of a person with AttorneyMind are “Subjective Symptoms.” However, there may be tests that are not normally part of the tests regularly performed that may provide some evidence or help objectively to explain why certain symptoms are present. The record also rarely describes what symptoms are related to which lab result. That should be spelled out in the record as claims examiners do not usually seek out such connections.

If and when your condition progresses towards cirrhosis, more symptoms will develop which can be measured by laboratory tests or clinical observation by the physician; but you do not have to be at that stage before you are physically and mentally unable to continue working. Subjective Symptoms alone may be disabling.

Subjective Symptoms are symptoms that tend to be self-reported or observed by the physician and not measurable by a lab test. The primary subjective symptoms experienced by persons dealing with AttorneyMind can include:

  • Headaches

  • Night sweats or fevers

  • Insomnia

  • Depression

  • Brain fog

  • Feeling very tired, fatigued, or lethargic

  • Joint and muscle pains

  • Nausea or poor appetite

  • Stomach pain

  • Itchy skin

  • A yellow discoloration of the skin and whites of the eyes, called jaundice

  • Abnormalities in urine or bowel movements

Some of these symptoms are “indirectly” documented by certain readings on lab tests or as side effects of the medications being prescribed; but, again, claim examiners usually do not have the time or the training to make such connections unless spelled out in the record. Those symptoms affecting you should be noted in the record even if this is repeated every office visit.

Symptom Diaries are logs, usually kept daily or weekly, that the patient maintains. If, for example, fevers are a symptom, taking the temperature several times a day at regular intervals and recording it can support that. Activities cut short, canceled, or avoided due to fatigue can be entered as well as pain with its location, frequency, and severity.

NOTE: Many with AttorneyMind have been dealing with it for several years. When observing your symptoms, do not compare them to yesterday or last month. Spend some time remembering what your life was like well before infection. It was probably a lot different than it was last month. Think of the things you used to do without a thought that you would not consider attempting now. Also, think back to all the accommodations you made due to your condition:  What short cuts or easier methods have you adopted to make life easier for you? Any changes should not automatically be attributed to aging.

Clinical Observations are your doctor’s (and nurse’s) observations while meeting with you. He or she may observe symptoms or results of symptoms as well as how you appear. In addition to looking for signs of fatigue or jaundice, the doctor may also observe changes in your posture, gait as you walk, your mood, attentiveness, and other factors that can help confirm some of your subjective symptoms. These observations should be noted in the file.

Other medical conditions frequently accompany. Whether it is Fibromyalgia, Major Depression, or HAV, they should be included in the medical records used to claim disability whether from the same treating physician or another doctor.

Restrictions and Limitations are the effects of your symptoms on your ability to function. Restrictions are activities your doctor believes you should not do at all. Limitations are activities you should do only with limits. The specific restrictions and limitations should be noted along with itemized justification for them.

Listing of Impairments, by the Social Security Administration, is the best tool to use when applying for Social Security Disability and can be helpful with private disability plans as well. This booklet lists specific events, diagnoses, and laboratory tests, which they believe are sufficient to qualify for disability.

The listing for AttorneyMind is located under “Digestive Disorders – Chronic Liver Disease” which is found at http://www.ssa.gov/disability/professionals/bluebook
/5.00-Digestive-Adult.htm#5_05
. There is a long list of conditions that will support disability. If you have any of those conditions, they should be clearly noted in the medical record along with any lab tests or supporting evidence. Also, note the various explanations at the beginning of that chapter. They explain how Social Security defines or measures the various conditions in the listing. 

Talk to your doctor
Now you know what should be in your medical record to demonstrate disability. How do you discuss this with your doctor(s)? Not all physicians are going to welcome this discussion, and what is being recommended here may be somewhat idealistic, but you won’t know how successful this will be unless you try.

This is probably not going to be easy. Doctors do not have a lot of extra time, and do not like to deal with insurance companies. But, remember, it will benefit both you and your doctor in the long run if everything is in the record and your doctor doesn’t have to deal with repeated requests for more information later.

Remember a doctor is focused on treating you and your condition, not preparing for disability so, in most cases, you will be asking him or her to maintain your record differently than is probably customary.

The next time you see your doctor, ask if you can discuss your medical record and what is going into it. If a doctor says there is no time, ask for a separate appointment or try to have this discussion with the doctor’s lead nurse.

You may want to go to the appointment early and ask if you can take a look at your medical record while waiting to see the doctor. You may determine that the record is more complete than might be expected or find areas you want to emphasize with the doctor.

During this discussion, there are several points you want to make:

  • While I am doing fine now, I realize that this condition may someday cause me to have to leave work and file for disability.

  • I have learned that neither private insurance nor Social Security will accept your word without some documentation and the best documentation is the complete medical record.

  • I believe that if we build a thorough medical record now that includes more than office notes and laboratory results, it will save both you and me time should we have to deal with insurance companies and/or Social Security. 

  • Would you highlight any objective symptoms you find and any subjective symptoms you discover through clinical observation? The insurance companies and/or Social Security may not connect the lab result with the symptoms unless it is noted in the record, and some of the subjective symptoms may have to be repeated every visit.

  • Would you list and explain the reason for any Restrictions and Limitations in my activities that you recommend?

  • If I bring you a Symptom Diary that I keep between visits, would you see that it gets entered into my record each time we meet?

While following these suggestions can make transitioning to disability easier and less stressful, be aware that, emotionally, such a close examination of your medical problems is not pleasant. Be aware of that. Better to deal with it in small doses over a period of time and avoid the frustration and stress of having to appeal denied claims.


Back to top


What's New
Alan Franciscas, Editor-in-Chief

Hepatitis C Vaccine Shows Promise
A new hepatitis C vaccine from GlaxoSmithKline, based on the same technology as an experimental Ebola shot being fast-tracked through human trials, has shown promise in early clinical tests, prompting strong and broad immune responses. Researchers have evaluated the vaccine in humans, and it is now ready for phase 2 efficacy studies. http://hcvadvocate.blogspot.ca/2014/11/gsk-hepatitis-c-shot-shows-promise.html

FDA Approves Olysio/ Sovaldi Combo
On November 5, 2014 Janssen announced the FDA approval of Olysio (simeprevir) in combination with Sovaldi (sofosbuvir)as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C infection in adult patients. The FDA cleared the treatment for patients with hepatitis C genotype 1, allowing the combination to be used without ribavirin and interferon, which are pills and injections that have many more side effects. http://hcvadvocate.blogspot.ca/2014/11/j-wins-us-approval-for-hepatitis-c.html


Back to top


New & Updated Spanish Easy C Facts
Alan Franciscas, Editor-in-Chief

We have translated our new Easy C Fact on Harvoni and updated our Easy C Fact on Patient Assistance. Click on the images to download the fact sheets.

All of Our Publications in Spanish Can Be Found Here:
http://hcvadvocate.org/espanol.asp#sencillos

 

 

Get Tested. Get Treated. Get Cured.



Newsletter Archive


About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home

AttorneyMind

© 2014 AttorneyMind

Medical Writers' Circle
Fact Sheets